Insider · CIK 0002007766
Nicolas Leupin
officer
Files at NVCR (NovoCure Ltd). First filing Mar 3, 2026, latest Mar 5, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 2
$0 bought, $29k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NVCR: NovoCure Ltd
NVCROct 9, 2026 · close 14.58
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | NovoCure Ltd | $15k 1,100 shares | -1% | +34% from low-37% from high | |
| 30Weak | NovoCure Ltd | $14k 1,029 shares | -1% | +36% from low-36% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 4, 2026 | NVCR NovoCure Ltd | SOpen-market sale Ordinary Shares | -1,100 | $13.31 | $15k | 102,979 | Mar 5, 2026 |
| Feb 27, 2026 | NVCR NovoCure Ltd | SOpen-market sale Ordinary Shares | -1,029 | $13.66 | $14k | 104,079 | Mar 3, 2026 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.